Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Marie E EdwardsFouad T ChebibMaria V IrazabalTroy G OfstieLisa A BungumAndrew J MetzgerSarah R SenumMarie C HoganZiad M El-ZoghbyTimothy L KlinePeter C HarrisFrank S CzerwiecVicente E TorresPublished in: Clinical journal of the American Society of Nephrology : CJASN (2018)
Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.